Orofacial manifestations and dental treatment considerations in patients with tuberous sclerosis complex: a case report

Background: Tuberous sclerosis complex (TSC1/TSC2, Online Mendelian Inheritance in Man (OMIM) # 191100/613254) is a rare autosomal dominant genetic disorder characterized by the development of benign tumors in multiple organs, and its diagnosis is based on both genetic testing and clinical evaluation. The severity of TSC varies significantly, from being asymptomatic to posing potential life-threatening risks. Case: This study reports a case of TSC exhibiting all orofacial diagnostic features, illustrates detailed characteristics of these features clinically and histologically, and discusses the additional considerations or pitfalls for diagnosing TSC based solely on orofacial manifestations. The case also inspires the importance of detecting and managing the central cusp in TSC patients, showcasing its potential to spark new research directions in TSC within dentistry. Conclusions: By promptly and accurately identifying the orofacial diagnostic features of TSC, dental practitioners can offer effective dental treatment planning for such patients and potentially aid in the early diagnosis of TSC, thereby enhancing the patient’s overall prognosis.

Tuberous sclerosis complex; Orofacial manifestation; Early diagnosis; Dental treatment; Central cusp

[1] Man A, Di Scipio M, Grewal S, Suk Y, Trinari E, Ejaz R, et al. The genetics of tuberous sclerosis complex and related mTORopathies: current understanding and future directions. Genes. 2024; 15: 332.

[2] Hwang SK, Lee JH, Yang JE, Lim CS, Lee JA, Lee YS, et al. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. Molecular Brain. 2016; 9: 56.

[3] Islam MP. Tuberous sclerosis complex. Seminars in Pediatric Neurology. 2021; 37: 100875.

[4] Curatolo P, Trivisano M, Specchio N. Updated genotype-phenotype correlations in TSC. Seminars in Pediatric Neurology. 2023; 47: 101086.

[5] Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. International tuberous sclerosis complex consensus group. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology. 2021; 123: 50–66.

[6] Luo C, Ye WR, Shi W, Yin P, Chen C, He YB, et al. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet Journal of Rare Diseases. 2022; 17: 106.

[7] Peng JH, Tu HP, Hong CH. A population-based study to estimate survival and standardized mortality of tuberous sclerosis complex (TSC) in Taiwan. Orphanet Journal of Rare Diseases. 2021; 16: 335.

[8] Liu M, Ye J, You X. An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients. Child’s Nervous System. 2024; 40: 823–829.

[9] Golec W, Sołowiej E, Strzelecka J, Jurkiewicz E, Jóźwiak S. Vigabatrin—new data on indications and safety in paediatric epilepsy. Polish Journal of Neurology and Neurosurgery. 2021; 55: 429–439.

[10] Mishra A, Pandey RK. Fibro-epithelial polyps in children: a report of two cases with a literature review. Intractable Rare Diseases Research. 2016; 5: 129–132.

[11] Jacinthe L, Jean-Hughes C, Mathilde L, Ugo O, Romain L, Fabrice C. Oral and skin manifestations of tuberous sclerosis complex. Journal of Oral Medicine and Oral Surgery. 2019; 25: 34.

[12] Savell AS, Norton K, Heaphy MR III. Folliculocystic and collagen hamartoma: a subset of fibrous cephalic plaque. Cureus. 2021; 13: e14987.

[13] Cascarino M, Leclerc-Mercier S. Histological patterns of skin lesions in tuberous sclerosis complex: a panorama. Dermatopathology. 2021; 8: 236–252.

[14] Sparling JD, Hong CH, Brahim JS, Moss J, Darling TN. Oral findings in 58 adults with tuberous sclerosis complex. Journal of the American Academy of Dermatology. 2007; 56: 786–790.

[15] Gosnell ES, Krueger D, Ruck P, Buff-Lindner AH, Horn PS, Griffith M. Oral manifestations and quality of life in children with tuberous sclerosis complex: a descriptive study. Pediatric Dentistry. 2021; 43: 140–144.

[16] Tovani-Palone MR, Bistagnino F, Shah PA. Multidisciplinary team for patients with neurocutaneous syndromes: the little discussed importance of dentistry. Clinics. 2024; 79: 100332.

[17] Agrawal AA. Gingival enlargements: differential diagnosis and review of literature. World Journal of Clinical Cases. 2015; 3: 779–788.

[18] Ding Y, Wang J, Zhou H, Li T, Zhou S, Wang Y. Assessment of tuberous sclerosis-associated neuropsychiatric disorders using the MINI-KID tool: a pediatric case-control study. Orphanet Journal of Rare Diseases. 2021; 16: 181.

[19] Teng JM, Cowen EW, Wataya-Kaneda M, Gosnell ES, Witman PM, Hebert AA, et al. Dermatologic and dental aspects of the 2012 international tuberous sclerosis complex consensus statements. JAMA Dermatology. 2014; 150: 1095–1101.

[20] Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, et al. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars in Oncology. 2023; 50: 7–10.

[21] Sonis ST, Villa A. A new hypothesis describing the pathogenesis of oral mucosal injury associated with the Mammalian Target of Rapamycin (mTOR) inhibitors. Cancers. 2023; 16: 68.

[22] Sabarudin MA, Taib H, Wan Mohamad WM. Refining the mechanism of drug-influenced gingival enlargement and its management. Cureus. 2022; 14: e25009.

[23] Lerdrungroj K, Banomyong D, Nakornchai S, Ngoenwiwatkul Y, Porkaew P. Outcomes and predisposing factors of two prophylactic treatments in dens evaginatus premolars: a retrospective study. Journal of Endodontics. 2022; 48: 864–871.

[24] Jose EA, Palathingal P, Mathew MG, Khan MM. Ten-cusped primary molar tooth: a rare entity with literature review. Journal of Oral and Maxillofacial Pathology. 2020; 24: 176–178.

[25] Nie X, Zheng J, Cruciger M, Yang P, Mao JJ. mTOR plays a pivotal role in multiple processes of enamel organ development principally through the mTORC1 pathway and in part via regulating cytoskeleton dynamics. Developmental Biology. 2020; 467: 77–87.

[26] Taga H, Yonenaga K, Eno Y, Yasumitsu T, Hatano T, Matsuo A, et al. Significant cases of central cusps, enamel pits, and oral fibromas in tuberous sclerosis complex. Odontology. 2021; 109: 279–283.

[27] American Academy of Pediatric Dentistry. Caries-risk assessment and management for infants, children, and adolescents. The Reference Manual of Pediatric Dentistry (pp. 301–307). American Academy of Pediatric Dentistry: Chicago, Ill. 2023.